× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

RECOVERY (plasma) , 2021   NCT04381936 5 days ago

convalescent plasma treatment vs. control - COVID 19 hospitalized NA risk of bias

  • inconclusive results for: 28-day mortality

risk of bias not assessable

meta-analysis

Libster , 2020   NCT04479163 7 days ago

convalescent plasma treatment vs. placebo - COVID-19 mild to moderate low risk of bias

  • demonstrated 48 % decrease in severe respiratory disease
  • inconclusive results for: death from Covid-19; admission to intensive care unit

meta-analysis

REMAP-CAP tocilizumab , 2021   NCT02735707 2 weeks ago

tocilizumab vs. standard of care - COVID-19 severe or critically some concern in risk of bias

  • suggested 30 % decrease in in hospital deaths
  • demonstrated 64 % increase in Organ support-free days

meta-analysis

REMAP-CAP sarilumab , 2021   NCT02735707 2 weeks ago

sarilumab vs. standard of care - COVID-19 severe or critically some concern in risk of bias

  • demonstrated 76 % increase in Organ support-free days
  • inconclusive results for: In-hospital deaths

meta-analysis

ACTIV-3/TICO LY-CoV555 , 2020   NCT04501978 4 weeks ago

neutralizing antibody vs. placebo - COVID 19 hospitalized low risk of bias

  • inconclusive results for: deaths; clinical improvement at day 5; Time to Hospital Discharge; Time until Sustained Recovery

meta-analysis

Moderna/NIH phase 3 (study 301) , 2020   NCT04470427 5 weeks ago

Moderna COVID-19 vaccine vs. placebo - COVID-19 prophylaxis some concern in risk of bias

  • suggested 95 % decrease in laboratory-confirmed Covid-19 after 1 dose
  • suggested 93 % decrease in Symptomatic Covid-19, ITT
  • demonstrated 94 % decrease in laboratory-confirmed Covid-19
  • demonstrated 98 % decrease in severe cases of Covid-19 after 2 doses
  • inconclusive results for: death; any SAE; any AE (unsolicited); appendicitis; arthralgia, grade 3-4; fever, grade 3-4; hypersensitivity, all; grade 3 adenopathy; severe lymphadenopathy; Musculoskeletal and connective tissue disorders; mylgia, grade 3-4; any local reaction (2nd injection); grade 3-4 local adverse reaction; any systemic reaction (2nd injection); grade 3-4 systemic adverse reaction

meta-analysis

RECOVERY-AZI (Horby) , 2020   NCT04381936 5 weeks ago

azithromycin vs. standard of care - COVID 19 hospitalized some concern in risk of bias

    Preliminary findings based on a data cut on 30 November. Final results will be made available after the last patient has completed the 28-day follow-up period for the primary outcome on 25 December 2020

  • inconclusive results for: death (28d); invasive mechanical ventilation or death; discharged from hospital alive within 28 days; any major cardiac arrhytmia

meta-analysis

ACTT-2 (Kalil) , 2020   NCT04401579 2 months ago

baricitinib plus remdesivir vs. remdesivir - COVID 19 hospitalized low risk of bias

  • demonstrated 16 % increase in time to recovery
  • suggested 31 % decrease in Death or progression to invasive mechanical ventilation
  • suggested 50 % decrease in serious or nonserious adverse events of new infection
  • inconclusive results for: death at 28 days; improvement in clinical status at day 15

meta-analysis

Lenze , 2020   NCT04342663 2 months ago

fluvoxamine vs. placebo - COVID 19 outpatients some concern in risk of bias

  • demonstrated 93 % decrease in Clinical deterioration
  • inconclusive results for: serious AE; any AE

meta-analysis

PlasmAr , 2020   NCT04344535 2 months ago

convalescent plasma treatment vs. control - COVID-19 severe or critically low risk of bias

  • inconclusive results for: death; clinical improvement; serious event

meta-analysis

Demonstrated: statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons